Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 6/2022

10-11-2022 | Testosterone

The anabolic applications of androgens in older adults with functional limitations

Authors: Arijeet K. Gattu, Anna L. Goldman, Ezgi Caliskan Guzelce, Francesca Galbiati, Shalender Bhasin

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 6/2022

Login to get access

Abstract

Aging is associated with a progressive decrease in skeletal muscle mass, strength and power and impairment of physical function. Serum testosterone concentrations in men decrease with advancing age due to defects at all levels of the hypothalamic-pituitary–testicular axis. Testosterone administration increases skeletal muscle mass, strength and power in older men with low or low normal testosterone levels, but the effects on performance-based measures of physical function have been inconsistent. Adequately powered randomized trials are needed to determine the long-term safety and efficacy of testosterone in improving physical function and quality of life in older adults with functional limitations.
Literature
1.
Jin L, Walters WA, Handelsman J. The effects of chronic high dose androgen or estrogen treatment on the human prostate. J Clin Endocrinol Metab. 1996;81(12):4290–5.
2.
Dutta C, Hadley E. The significance of sarcopenia in old age. J Gerontol Series A Biol Sci Med Sci. 1995;50 Spec No(Special), 1–4.
3.
Proctor D, Balagopal P, Nair KS. Age-related Sarcopenia in humans is associated with reduced synthetic rates of specific muscle proteins. J Nutr. 1998;128(2):351S–355S.CrossRef
4.
Bassey EJ, Fiatarone M, Oneill E, Kelly M, Evans W, Lipsitz L. Leg extensor power and functional performance in very old men and women. Clin Sci. 1992;82(3):321–7.CrossRef
5.
Rantanen T, Avela J. Leg Extension Power and Walking Speed in Very Old People Living Independently. J Gerontol Series A, Biol Sci Med Sci. 1997;52A(4):M225–31.CrossRef
6.
Frontera WR, Hughes VA, Lutz KJ, Evans WJ. A cross-sectional study of muscle strength and mass in 45- to 78-yr-old men and women. J Appl Physiol. 1991;71(2):644–50.CrossRef
7.
Skelton DS, Greig CA, Davies JM, Young A. Strength, Power and Related Functional Ability of Healthy People Aged 65–89 Years. Age Ageing. 1994;23(5):371–7.CrossRef
8.
Krasnoff BJ, Basaria S, Pencina MJ, Jasuja GK, Vasan RS, Ulloor J, Zhang A, Coviello A, Kelly-Hayes M, D’Agostino RB, Wolf PA, Bhasin S, Murabito JM. Free Testosterone Levels Are Associated with Mobility Limitation and Physical Performance in Community-Dwelling Men: The Framingham Offspring Study. J Clin Endocrinol Metab. 2010;95(6):2790–9.CrossRef
9.
López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The Hallmarks of Aging. Cell. 2013;153(6):1194–217.CrossRef
10.
Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT, EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35.CrossRef
11.
Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, Wang PY, Nielson C, Wu F, Tajar A, Labrie F, Vesper H, Zhang A, Ulloor J, Singh R, D’Agostino R, Vasan RS. Reference Ranges for Testosterone in Men Generated Using Liquid Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts. J Clin Endocrinol Metab. 2011;96(8):2430–9.CrossRef
12.
Orwoll E, Lambert LC, Marshall LM, Phipps K, Blank J, Barrett-Connor E, Cauley J, Ensrud K, Cummings S. Testosterone and Estradiol among Older Men. J Clin Endocrinol Metab. 2006;91(4):1336–44.CrossRef
13.
Travison TG, Vesper HW, Orwoll E, Wu F, Kaufman JM, Wang Y, Lapauw B, Fiers T, Matsumoto AM, Bhasin S. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102(4):1161–73.CrossRef
14.
Orwoll E, Lambert LC, Marshall LM, Blank J, Barrett-Connor E, Cauley J, Ensrud K, Cummings SR. Endogenous Testosterone Levels, Physical Performance, and Fall Risk in Older Men. Arch Intern Med. 2006;166(19):2124–31.CrossRef
15.
Travison TG, Nguyen A-H, Naganathan V, Stanaway FF, Blyth FM, Cumming RG, Le Couteur DG, Sambrook PN, Handelsman DJ. Changes in Reproductive Hormone Concentrations Predict the Prevalence and Progression of the Frailty Syndrome in Older Men: The Concord Health and Ageing in Men Project. J Clin Endocrinol Metab. 2011;96(8):2464–74.CrossRef
16.
Hyde Z, Flicker L, Almeida OP, Hankey GJ, McCaul KA, Chubb SAP, Yeap BB. Low Free Testosterone Predicts Frailty in Older Men: The Health in Men Study. J Clin Endocrinol Metab. 2010;95(7):3165–72.CrossRef
17.
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in healthy young men. Am J Physiol - Endocrinol Metab. 2001;281(6):1172–81.CrossRef
18.
Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, Bhasin S. Testosterone Dose-Dependently Increases Maximal Voluntary Strength and Leg Power but Does Not Affect Fatigability or Specific Tension. J Clin Endocrinol Metab. 2003;88(4):1478–85.CrossRef
19.
Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal Men. N Engl J Med. 1996;335(1):1–7.CrossRef
20.
Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, Dike M, Sinha-Hikim I, Shen R, Hays RD, Beall G. Testosterone Replacement and Resistance Exercise in HIV-Infected Men With Weight Loss and Low Testosterone Levels. JAMA. 2000;283(6):763–70.CrossRef
21.
Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER 3rd, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS. Testosterone Trials Investigators. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611–24.CrossRef
22.
Jaitovich A, Barreiro E. Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease What We Know and Can Do for Our Patients. Am J Respir Crit Care Med. 2018;198(2):175–86.CrossRef
23.
Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA. 1999;281(14):1275–81.CrossRef
24.
Bhasin S, Apovian CM, Travison TG, Pencina K, Moore LL, Huang G, Campbell WW, Li Z, Howland AS, Chen R, Knapp PE, Singer MR, Shah M, Secinaro K, Eder RV, Hally K, Schram H, Bearup R, Beleva YM, Basaria S. Effect of Protein Intake on Lean Body Mass in Functionally Limited Older Men: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(4):530–41.CrossRef
25.
Storer T, Basaria S, Traustadottir T, Harman SM, Pencina K, Li Z, Travison TG, Miciek R, Tsitouras P, Hally K, Huang G, Bhasin S. Effects of Testosterone Supplementation for 3-Years on Muscle Performance and Physical Function in Older Men. J Clin Endocrinol Metab. 2017;102(2):583–93.
26.
Travison TG, Basaria S, Storer TW, Jette AM, Miciek R, Farwell WR, Choong K, Lakshman K, Mazer NA, Coviello AD, Knapp PE, Ulloor J, Zhang A, Brooks B, Nguyen A-H, Eder R, LeBrasseur N, Elmi A, Appleman E, Brierley L, Bhasin G, Bhatia A, Lazzari A, Davis S, Ni P, Collins L, Bhasin S. Clinical Meaningfulness of the Changes in Muscle Performance and Physical Function Associated With Testosterone Administration in Older Men With Mobility Limitation. J Gerontol Series A Biol Sci Med Sci. 2011;66A(10):1090–9.CrossRef
27.
Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MDL, Adams JE, Oldham JA, Wu FCW. Effects of Testosterone on Muscle Strength, Physical Function, Body Composition, and Quality of Life in Intermediate-Frail and Frail Elderly Men: A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Endocrinol Metab. 2010;95(2):639–50.CrossRef
28.
Emmelot-Vonk MH, Verhaar HJJ, Nakhai Pour HR, Aleman A, Lock TMTW, Bosch JLHR, Grobbee DE, van der Schouw YT. Effect of Testosterone Supplementation on Functional Mobility, Cognition, and Other Parameters in Older Men : A Randomized Controlled Trial. JAMA, J Am Med Assoc. 2008;299(1):39–52.CrossRef
29.
Nair K, Rizza RA, O’Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Man CD, Tindall DJ, Melton LJ, Smith GE, Khosla S, Jensen MD. DHEA in Elderly Women and DHEA or Testosterone in Elderly Men. N Engl J Med. 2006;355(16):1647–59.CrossRef
30.
Sheffield-Moore M, Dillon EL, Casperson SL, Gilkison CR, Paddon-Jones D, Durham WJ, Grady JJ, Urban RJ. A Randomized Pilot Study of Monthly Cycled Testosterone Replacement or Continuous Testosterone Replacement Versus Placebo in Older Men. J Clin Endocrinol Metab. 2011;96(11):E1831–7.CrossRef
31.
Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous Testosterone (T) Alone or with Finasteride Increases Physical Performance, Grip Strength, and Lean Body Mass in Older Men with Low Serum T. J Clin Endocrinol Metab. 2005;90(3):1502–10.CrossRef
32.
Borst SE, Yarrow JF, Conover CF, Nseyo U, Meuleman JR, Lipinska JA, Braith RW, Beck DT, Martin JS, Morrow M, Roessner S, Beggs LA, McCoy SC, Cannady DF, Shuster JJ. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab. 2014;306(4):E433–42.CrossRef
33.
Traustadóttir T, Harman SM, Tsitouras P, Pencina KM, Li Z, Travison TG, Eder R, Miciek R, McKinnon J, Woodbury E, Basaria S, Bhasin S, Storer TW. Long-Term Testosterone Supplementation in Older Men Attenuates Age-Related Decline in Aerobic Capacity. J Clin Endocrinol Metab. 2018;103(8):2861–9.CrossRef
34.
Bhasin S, Ellenberg SS, Storer TW, Basaria S, Pahor M, Stephens-Shields AJ, Cauley JA, Ensrud KE, Farrar JT, Cella D, Matsumoto AM, Cunningham GR, Swerdloff RS, Wang C, Lewis CE, Molitch ME, Barrett-Connor E, Crandall JP, Hou X, Gill TM. Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. Lancet Diabetes Endocrinol. 2018;6(11):879–90.CrossRef
35.
Santi D, Spaggiari G, Vena W, Pizzocaro A, Maggi M, Rochira V, Corona G. The Prevalence of Hypogonadism and the Effectiveness of Androgen Administration on Body Composition in HIV-Infected Men: A Meta-Analysis. Cells (Basel, Switzerland). 2021;10(8):2067.
36.
Monroe AK, Dobs AS, Xu X, Palella FJ, Kingsley LA, Witt MD, Brown TT. Sex Hormones, Insulin Resistance, and Diabetes Mellitus Among Men With or at Risk for HIV Infection. JAIDS- J Acquir Immune Defic Syndr. 2011;58(2):173–80.CrossRef
37.
Wunder DM, Bersinger NA, Fux CA, Mueller NJ, Hirschel B, Cavassini M, Elzi L, Schmid P, Bernasconi E, Mueller B, Furrer H. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir Ther. 2007;12(2):261–5.CrossRef
38.
Jasuja R, Bhasin S, Rose AJ, Reisman JI, Skolnik A, Berlowitz DR, Gifford AL. Use of testosterone in men infected with human immunodeficiency virus in the veterans healthcare system. AIDS Care. 2018;30(10):1207–14.CrossRef
39.
Haberlen SA, Jacobson L, Palella F, Dobs A, Plankey M, Lake J, Kingsley L, Stall R, Post W, Brown T. To T or not to T: Differences in Testosterone Use and Discontinuation by HIV Serostatus among Men who Have Sex with Men. HIV Med. 2018;19(9):634–44.CrossRef
40.
Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis. 2002;2(11):692–9.CrossRef
41.
Choi GPB, Storer TW, Calof OM, Woodhouse L, Singh AB, Padero C, Mac RP, Sinha-Hikim I, Shen R, Dzekov J, Dzekov C, Kushnir MM, Rockwood AL, Meikle AW, Lee ML, Hays RD, Bhasin S. Effects of Testosterone Replacement in Human Immunodeficiency Virus-Infected Women with Weight Loss. J Clin Endocrinol Metab. 2005;90(3):1531–41.CrossRef
42.
Dolan WS, Aliabadi N, Sullivan MP, Basgoz N, Davis B, Grinspoon S. Effects of Testosterone Administration in Human Immunodeficiency Virus-Infected Women With Low Weight: A Randomized Placebo-Controlled Study. Arch Intern Med. 2004;164(8):897–904.CrossRef
43.
Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, Burrows B, Walsh M, Hayden D, Parlman K, Anderson E, Basgoz N, Klibanski A. Effects of androgen administration in men with the AIDS wasting syndrome - A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;129(1):18–26.CrossRef
44.
Strawford A, Barbieri T, Van Loan M, Parks E, Catlin D, Barton N, Neese R, Christiansen M, King J, Hellerstein MK. Resistance Exercise and Supraphysiologic Androgen Therapy in Eugonadal Men With HIV-Related Weight Loss: A Randomized Controlled Trial. JAMA, J Am Med Assoc. 1999;281(14):1282–90.CrossRef
45.
Casaburi R, Bhasin S, Cosentino L, Porszasz J, Somfay A, Lewis MI, Fournier M, Storer TW. Effects of Testosterone and Resistance Training in Men with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2004;170(8):870–8.CrossRef
46.
Yeh DB, Kramer T. Reversal of COPD-Associated Weight Loss Using the Anabolic Agent Oxandrolone. Chest. 2002;122(2):421–8.CrossRef
47.
Schols AMWJ, Soeters PB, Mostert R, Pluymers RJ, Wounters EFM. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease: a placebo-controlled randomized trial. Am J Respir Crit Care Med. 1995;152(4):1268–74.CrossRef
48.
Crawford LPY, Kean MT, Bleasel JF, Handelsman DJ. Randomized Placebo-Controlled Trial of Androgen Effects on Muscle and Bone in Men Requiring Long-Term Systemic Glucocorticoid Treatment. J Clin Endocrinol Metab. 2003;88(7):3167–76.CrossRef
49.
Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Osteoporos Int. 1996;6(S1):274–274.CrossRef
50.
Bhasin BJP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–44.CrossRef
51.
Li H, Guo Y, Yang Z, Roy M, Guo Q. The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis. Burns : J Int Soc Burn Injuries. 2016;42(4):717–27.CrossRef
52.
Ponce OJ, Spencer-Bonilla G, Alvarez-Villalobos N, Serrano V, Singh-Ospina N, Rodriguez-Gutierrez R, Salcido-Montenegro A, Benkhadra R, Prokop LJ, Bhasin S, Brito JP. The Efficacy and Adverse Events of Testosterone Replacement Therapy in Hypogonadal Men: A Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab. 2018;103(5):1745–54.CrossRef
53.
Bhasin S, Valderrábano RJ, Gagliano-Jucá T. Age-Related Changes in the Male Reproductive System. In KR Feingold (Eds.) et. al., Endotext. 2022. MDText.com, Inc.
54.
Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100(3):170–83.CrossRef
55.
Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan. J Androl. 2003;24(3):299–311.CrossRef
56.
Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, Pencina KM, Vita J, Dzekov C, Mazer NA, Coviello AD, Knapp PE, Hally K, Pinjic E, Yan M, Storer TW, Bhasin S. Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial. JAMA, J Am Med Assoc. 2015;314(6):570–81.CrossRef
57.
Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, Wenger NK, Bhasin S, Barrett-Connor E, Swerdloff RS, Stephens-Shields A, Cauley JA, Crandall JP, Cunningham GR, Ensrud KE, Gill TM, Matsumoto AM, Molitch ME, Nakanishi R, Nezarat N, Matsumoto S, Hou X, Basaria S, Diem SJ, Wang C, Cifelli D, Snyder PJ. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA. 2017;317(7):708–16.CrossRef
58.
Bhasin S, Lincoff AM, Basaria S, Bauer DC, Boden WE, Cunningham GR, Davey D, Dubcenco E, Fukumoto S, Garcia M, Granger CB, Kalahasti V, Khera M, Miller MG, Mitchell LM, O’Leary MP, Pencina KM, Snyder PJ, Thompson IM Jr, Travison TG, Wolski K, Nissen SE, TRAVERSE Study Investigators. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J. 2022;245:41–50.CrossRef
59.
Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens Stimulate Myogenic Differentiation and Inhibit Adipogenesis in C3H 10T1/2 Pluripotent Cells through an Androgen Receptor-Mediated Pathway. Endocrinology (Philadelphia). 2003;144(11):5081–8.CrossRef
60.
Singh R, Artaza JN, Taylor WE, Braga M, Yuan X, Gonzalez-Cadavid NF, Bhasin S. Testosterone Inhibits Adipogenic Differentiation in 3T3-L1 Cells: Nuclear Translocation of Androgen Receptor Complex with β-Catenin and T-Cell Factor 4 May Bypass Canonical Wnt Signaling to Down-Regulate Adipogenic Transcription Factors. Endocrinology (Philadelphia). 2006;147(1):141–54.CrossRef
61.
Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol - Endocrinol Metab. 2002;282(3):601–7.CrossRef
62.
Sheffield-Moore M, Urban R, Wolf S, Jiang J, Catlin D, Herndon D, Wolfe R, Ferrando A. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab. 1999;84(8):2705–11.
63.
Bhasin S, Travison TG, Storer TW, Lakshman K, Kaushik M, Mazer NA, Ngyuen A-H, Davda MN, Jara H, Aakil A, Anderson S, Knapp PE, Hanka S, Mohammed N, Daou P, Miciek R, Ulloor J, Zhang A, Brooks B, Brooks B, Orwoll K, Hede-Brierley L, Eder R, Elmi A, Bhasin G, Collins L, Singh R, Basaria S. Effect of Testosterone Supplementation With and Without a Dual 5α-Reductase Inhibitor on Fat-Free Mass in Men With Suppressed Testosterone Production: A Randomized Controlled Trial. JAMA, J Am Med Assoc. 2012;307(9):931–9.CrossRef
64.
Finkelstein LH, Burnett-Bowie S-AM, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. N Engl J Med. 2013;369(11):1011–22.CrossRef
65.
Scragg JRD, Channer KS, Jones TH, Peers C. Testosterone is a potent inhibitor of L-type Ca(2+) channels. Biochem Biophys Res Commun. 2004;318(2):503–6.CrossRef
66.
English KM, Jones R, Jones T, Morice A, Channer K. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest. 2002;25(5):455–8.CrossRef
67.
Mills SV, Wiedmeier V. Effects of castration and androgen replacement on the hemodynamics of penile erection in the rat. Biol Reprod. 1994;51(2):234–8.CrossRef
68.
Fernandes VS, Barahona MV, Recio P, Martínez-Sáenz A, Ribeiro AS, Contreras C, Martínez AC, Bustamante S, Carballido J, García-Sacristán A, Prieto D, Hernández M. Mechanisms involved in testosterone-induced relaxation to the pig urinary bladder neck. Steroids. 2012;77(5):394–402.CrossRef
69.
Perusquia M, Stallone JN. Do androgens play a beneficial role in the regulation of vascular tone? Nongenomic vascular effects of testosterone metabolites. Am J Physiol - Heart Circ Physiol. 2010;298(5):1301–7.CrossRef
70.
Montaño LM, Espinoza J, Flores-Soto E, Chávez J, Perusquía M. Androgens are bronchoactive drugs that act by relaxing airway smooth muscle and preventing bronchospasm. J Endocrinol. 2014;222(1):1–13.CrossRef
71.
Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of Graded Doses of Testosterone on Erythropoiesis in Healthy Young and Older Men. J Clin Endocrinol Metab. 2008;93(3):914–9.CrossRef
72.
Bhasin S, Ellenberg SS, Storer TW, Basaria S, Pahor M, Cauley JA, Ensrud KE, Farrar JT, Cella D, Matsumoto AM, Cunningham GR, Swerdloff RS, Wang C, Lewis CE, Molitch ME, Barrett-Connor E, Crandall JP, Stephens-Shields AJ, Hou X, Preston P, Cifelli D, Snyder PJ, Gill TM. The Effects of Testosterone Replacement on Self-reported and Performance-based Measures of Mobility in Older Men with Mobility Limitation and Low Testosterone Levels: A Placebo-Controlled Trial. Lancet Diabetes Endocrinol. 2018;6(11):879–90.CrossRef
73.
Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care. 2009;12(3):232–40.CrossRef
74.
Narayanan R, Coss CC, Dalton JT. Development of selective androgen receptor modulators (SARMs). Mol Cell Endocrinol. 2018;465(C):134–42.CrossRef
75.
Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–21.CrossRef
76.
Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT. Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab. 2006;2(3):146–59.CrossRef
77.
Fragkaki AG, Angelis YS, Koupparis M, Tsantili-Kakoulidou A, Kokotos G, Georgakopoulos C. Structural characteristics of anabolic androgenic steroids contributing to binding to the androgen receptor and to their anabolic and androgenic activities Applied modifications in the steroidal structure. Steroids. 2009;74(2):172–97.CrossRef
78.
Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril. 1982;37(3):425–30.CrossRef
79.
Hoffman JR, Kraemer WJ, Bhasin S, Storer T, Ratamess NA, Haff GG, Willoughby DS, Rogol AD. Position Stand on Androgen and Human Growth Hormone Use. J Strength Cond Res. 2009;23(5 Suppl):S1–59.CrossRef
80.
Pencina KM, Burnett AL, Storer TW, Guo W, Li Z, Kibel AS, Huang G, Blouin M, Berry DL, Basaria S, Bhasin S. A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial. J Clin Endocrinol Metab. 2021;106(8):2171–86.CrossRef
81.
Dobs S, Prof Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–45.CrossRef
82.
Guo W, Pencina KM, Furtado JD, Sacks FM, Vaisar T, Cheng M, Sniderman AD, Page S, Bhasin S. Effect of Selective Androgen Receptor Modulator on Cholesterol Efflux Capacity, Size, and Subspecies of HDL Particles. J Endocrine Soc. 2022;6(8). (In press).
Metadata
Title
The anabolic applications of androgens in older adults with functional limitations
Authors
Arijeet K. Gattu
Anna L. Goldman
Ezgi Caliskan Guzelce
Francesca Galbiati
Shalender Bhasin
Publication date
10-11-2022
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 6/2022
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-022-09766-1

Other articles of this Issue 6/2022

Reviews in Endocrine and Metabolic Disorders 6/2022 Go to the issue

ReviewPaper

The medicalization of testosterone: reinventing the elixir of life

ReviewPaper

The role of testosterone in male sexual function

ReviewPaper

Androgens, aging, and prostate health

ReviewPaper

The role of testosterone, the androgen receptor, and hypothalamic-pituitary–gonadal axis in depression in ageing Men

ReviewPaper

Diagnosis of hypogonadism in ageing men

ReviewPaper

Obesity, type 2 diabetes, and testosterone in ageing men
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits